Psilocybin clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Psilocybin is a naturally occurring compound produced by several species of mushroom. This page summarises registered studies whose registry records mention psilocybin, using PsychoactiveMap's copy of the ClinicalTrials.gov registry.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 308 registered Psilocybin studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 102 | 33% |
| Not yet recruiting | 33 | 11% |
| Enrolling by invitation | 3 | 1% |
| Active, not recruiting | 33 | 11% |
| Completed | 96 | 31% |
| Terminated | 7 | 2% |
| Suspended | 2 | 1% |
| Withdrawn | 14 | 5% |
| Status not reported | 18 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 23 | 7% |
| Phase 1 | 111 | 36% |
| Phase 2 | 138 | 45% |
| Phase 3 | 14 | 5% |
| Not applicable | 15 | 5% |
| Not reported | 7 | 2% |
Countries
Country is taken from the study's linked research site. 11 of 308 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 190 | 62% |
| Canada | 39 | 13% |
| Switzerland | 20 | 6% |
| United Kingdom | 13 | 4% |
| France | 6 | 2% |
| Australia | 4 | 1% |
| Israel | 4 | 1% |
| Germany | 3 | 1% |
| Sweden | 3 | 1% |
| Belgium | 2 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 177 |
| 2020 to 2023 | 97 |
| 2015 to 2019 | 22 |
| 2010 to 2014 | 7 |
| Before 2010 | 5 |
Study design
- 301 interventional and 7 observational studies.
- Median planned or actual enrolment is 30 participants (range 2 to 572, across 296 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 77 |
| Cancer and end of life | 29 |
| Trauma and PTSD | 22 |
| Other substance use | 22 |
| Pain and headache | 22 |
| Alcohol use | 19 |
| Healthy volunteers | 17 |
| Anxiety | 12 |
Most recently started studies
The 25 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT06005662 | Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Withdrawn | Phase 2 | United States | 2027-04 |
| NCT07774702 | Psilocybin for Methamphetamine Use Disorder | Not yet recruiting | Phase 2 | United States | 2027-02 |
| NCT07566104 | Group PACBT for Depression | Not yet recruiting | Phase 2 | United States | 2027-01 |
| NCT07852832 | Effects of Psilocybin on Craving in Nicotine Dependence | Not yet recruiting | Phase 2 | Not reported | 2027-01 |
| NCT07719088 | Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07792538 | Psilocybin-Assisted Psychotherapy for Veterans With PTSD | Not yet recruiting | Phase 2 | Netherlands | 2026-12 |
| NCT07818720 | MLS101 Study in PMDD | Not yet recruiting | Phase 1 | Not reported | 2026-12 |
| NCT07833761 | ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | Not yet recruiting | Phase 1 | United States | 2026-12 |
| NCT07756736 | Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Not yet recruiting | Phase 2 | United States | 2026-11 |
| NCT07818564 | Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation | Recruiting | Phase 1 | United States | 2026-11 |
| NCT07791901 | MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial | Not yet recruiting | Phase 2 | Canada | 2026-10 |
| NCT07721467 | Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin | Recruiting | Phase 2 | United States | 2026-10 |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | Not yet recruiting | Phase 2 | Canada | 2026-09 |
| NCT07433452 | The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. | Not yet recruiting | Phase 1 | Not reported | 2026-09 |
| NCT07570654 | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | Recruiting | Phase 2 | United States | 2026-09 |
| NCT07693153 | The Effects of Psilocybin on Social Connectedness | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07745569 | Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | Not yet recruiting | Phase 2 | United States | 2026-08 |
| NCT06885996 | Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | Not yet recruiting | Phase 2 | Canada | 2026-08 |
| NCT07499583 | Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder | Not yet recruiting | Phase 1 | United States | 2026-08 |
| NCT07406828 | Psilocybin After Trauma Surgery for Pain | Not yet recruiting | Phase 1 | United States | 2026-07 |
| NCT07479550 | Anesthesia-Masked Psilocybin Therapy for Major Depression | Not yet recruiting | Phase 2 | United States | 2026-07 |
| NCT07607938 | Psilocybin as a Novel Therapy for Residual Anhedonia | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07610135 | Psilocybin Efficacy With or Without Pimavanserin Pretreatment | Recruiting | Phase 1 | United States | 2026-07 |
| NCT07737990 | Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | Enrolling by invitation | Not applicable | Canada | 2026-07 |
| NCT07565493 | Psilocybin Administration With 5-HT1a Blockade | Recruiting | Early Phase 1 | United States | 2026-06 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable